



6055 Lusk Boulevard
San Diego, CA 92121
Tel: 858 202-4900
Fax: 858 450-6849

NVENTA'S CEO TO PRESENT AT RODMAN & RENSHAW 8TH ANNUAL HEALTHCARE CONFERENCE

FOR IMMEDIATE RELEASE

November 2, 2006

San Diego, California USA – Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that Gregory M. McKee, the Company's President and Chief Executive Officer, will present at the Rodman & Renshaw 8th Annual Healthcare Conference at the Palace Hotel in New York at 9:10 a.m. Eastern Time on Wednesday, November 8.

Mr. McKee will provide an overview of the Company and an update on HspE7, its investigational therapeutic vaccine candidate for human papillomavirus (HPV)-related diseases.

The audio portion of the presentation will be webcast live and available subsequently by replay on the Rodman & Renshaw website at <http://www.wsw.com/webcast/rrshq10/tsx.nvn/>. The replay of the webcast will be available for 90 days after the live presentation. Following the presentation, the audio replay and presentation slides will be available for seven days on the Nventa website, www.nventacorp.com.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at www.nventacorp.com.

Contact:

Donna Slade
Director, Investor Relations
6055 Lusk Boulevard
San Diego, CA USA 92121
Tel: 858 202-4900
Fax: 858 450-6849
dslade@nventacorp.com